Telesis Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 27th of September, 2024.
25 hedge funds and large institutions have $12.3M invested in Telesis Bio, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
14% less funds holding
Funds holding: 29 → 25 (-4)
35% less capital invested
Capital invested by funds: $18.9M → $12.3M (-$6.54M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
61% less call options, than puts
Call options by funds: $32K | Put options by funds: $83K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$39K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.5K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$14.1K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$8.79K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$7.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$146K |
| 2 |
Prudential Financial
Newark,
New Jersey
|
-$29.4K |
| 3 |
Two Sigma Investments
New York
|
-$21.9K |
| 4 |
Millennium Management
New York
|
-$16.5K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$10.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Renaissance Technologies
New York
| – | -$146K | -5,128 | Closed |
|
|
27
Prudential Financial
Newark,
New Jersey
| – | -$29.4K | -1,033 | Closed |
|
|
28
Two Sigma Investments
New York
| – | -$21.9K | -770 | Closed |
|
|
29
Simplex Trading
Chicago,
Illinois
| – | -$10.5K | -431 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$1.51K | -53 | Closed |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$389 | -16 | -80% |
|
TBIO Hedge Fund Activity: Q3 2023 in Review
25 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Telesis Bio, Inc. Common Stock (TBIO) for Q3 2023, worth a combined $12.3M — down 35% from $18.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TBIO and 2 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Penn Capital Management, adding an estimated $39K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $146K sold.
- 25 institutional investors held Telesis Bio, Inc. Common Stock (TBIO) as of Q3 2023, down from 29 in Q2 2023.
- Funds reported $12.3M of Telesis Bio, Inc. Common Stock stock for Q3 2023, down 35% quarter-over-quarter.
- 2 funds opened new Telesis Bio, Inc. Common Stock positions in Q3 2023 and 5 closed out, a net change of -3 holders.
- The largest Telesis Bio, Inc. Common Stock buyer in Q3 2023 was Penn Capital Management, an estimated $39K added.
- The largest Telesis Bio, Inc. Common Stock seller in Q3 2023 was Renaissance Technologies, an estimated $146K sold.
Based on aggregated 13F filings for Q3 2023.